This database contains 173 studies, archived under the term: "etiology"
Click here to filter this large number of results.
An intensive exercise program improves motor performances in patients with dementia: translational model of geriatric rehabilitation
Schwenk, Michael,
Dutzi, Ilona,
Englert, Stefan,
Micol, William,
Najafi, Bijan,
Mohler, Jane,
Hauer, Klaus
Background: Translation of intensive exercise programs developed specifically for patients with dementia into clinical settings is lacking.; Objective: To determine if a progressive resistance and functional training program, previously evaluated in dementia outpatients, can be implemented in a geriatric inpatient setting in order to improve motor performances in patients with dementia.; Methods: Eligible patients in […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]
Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial
Scheltens, Philip,
Kamphuis, Patrick J. G. H.,
Verhey, Frans R.J.,
Olde Rikkert, Marcel G. M.,
Wurtman, Richard J.,
Wilkinson, David,
Twisk, Jos W.R.,
Kurz, Alexander
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]
Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study
Sabia, Séverine,
Elbaz, Alexis,
Dugravot, Aline,
Head, Jenny,
Shipley, Martin,
Hagger-Johnson, Gareth,
Kivimaki, Mika,
Singh-Manoux, Archana
Context: Smoking is a possible risk factor for dementia, although its impact may have been underestimated in elderly populations because of the shorter life span of smokers.; Objective: To examine the association between smoking history and cognitive decline in the transition from midlife to old age.; Design: Cohort study.; Setting: The Whitehall II study. The […]
Effects of a psychological intervention in a primary health care center for caregivers of dependent relatives: a randomized trial
Rodriguez-Sanchez, E.,
Patino-Alonso, M. C.,
Mora-Simon, S.,
Gomez-Marcos, M. A.,
Perez-Penaranda, A.,
Losada-Baltar, A.,
Garcia-Ortiz, L.
Purpose: To assess, in the context of Primary Health Care (PHC), the effect of a psychological intervention in mental health among caregivers (CGs) of dependent relatives.; Design and Methods: Randomized multicenter, controlled clinical trial. The 125 CGs included in the trial were receiving health care in PHC.; Inclusion Criteria: Identifying oneself as principal CG of […]
Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors
Reijmer, Yael D.,
van den Berg, Esther,
de Bresser, Jeroen,
Kessels, Roy P. C.,
Kappelle, L. Jaap,
Algra, Ale,
Biessels, Geert Jan
Background: Type 2 diabetes mellitus is associated with an increased risk of cognitive decline and dementia. We examined brain imaging correlates and vascular and metabolic risk factors of accelerated cognitive decline in patients with type 2 diabetes.; Methods: Cognitive functioning and brain volume as well as metabolic and vascular risk factors were assessed twice in […]
Agitation in nursing home residents with dementia (VIDEANT trial): effects of a cluster-randomized, controlled, guideline implementation trial
Rapp, Michael A.,
Mell, Thomas,
Majić, Tomislav,
Treusch, Yvonne,
Nordheim, Johanna,
Niemann-Mirmehdi, Mechthild,
Gutzmann, Hans,
Heinz, Andreas
Objective: To test the effect of a complex guideline-based intervention on agitation and psychotropic prescriptions.; Design, Setting, Participants: Cluster randomized controlled trial (VIDEANT) with blinded assessment of outcome in 18 nursing homes in Berlin, Germany, comprising 304 dementia patients.; Intervention: Training, support, and activity therapy intervention, delivered at the level of each nursing home, focusing […]
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial
Prieto-Alhambra, D.,
Judge, A.,
Arden, N. K.,
Cooper, C.,
Lyles, K. W.,
Javaid, M. K.
Unlabelled: Patients with cognitive impairment (CI) often do not receive secondary fracture prevention. Use of zoledronic acid led to a similar reduction in re-fracture risk but the survival benefit was limited to those without CI.; Introduction: We tested whether the effects of id (Zol) on re-frazoledronic accture and mortality differed in patients presenting with a […]
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
Porsteinsson, Anton P.,
Drye, Lea T.,
Pollock, Bruce G.,
Devanand, D. P.,
Frangakis, Constantine,
Ismail, Zahinoor,
Marano, Christopher,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Pelton, Gregory,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Shade, David M.,
Weintraub, Daniel,
Yesavage, Jerome,
Lyketsos, Constantine G.
Importance: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.; Objective: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, […]